RegulationFast Track (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Regenerative Medicine Advanced Therapy (United States)

Structure/Sequence

Sequence Code 1277314181

Source: *****

Clinical Trials associated with Equecabtagene Autoleucel

NCT06902844

/ RecruitingNot ApplicableIIT

A Study of Equecabtagene Autoleucel Injection (Eque-cel) in the Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).

Start Date05 Apr 2025

Sponsor / Collaborator

Nanjing IASO Biotherapeutics Co., Ltd.Startup

CTR20240952

/ RecruitingPhase 4

伊基奥仑赛注射液治疗复发/难治性多发性骨髓瘤患者的真实世界研究

[Translation] A real-world study of ikiorencel injection in patients with relapsed/refractory multiple myeloma

评价上市后真实世界中伊基奥仑赛注射液治疗复发/难治性多发性骨髓瘤成人患者的疗效和安全性。

[Translation]

To evaluate the efficacy and safety of ikiorencel injection in the treatment of adult patients with relapsed/refractory multiple myeloma in the real world after marketing.

Start Date15 Jul 2024

Sponsor / Collaborator

Nanjing Reindeer Biomedical Co., Ltd.

NCT06369935

/ Not yet recruitingNot ApplicableIIT

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data

Start Date20 Jun 2024

Sponsor / Collaborator

Peking University People's Hospital

100 Clinical Results associated with Equecabtagene Autoleucel

100 Translational Medicine associated with Equecabtagene Autoleucel

100 Patents (Medical) associated with Equecabtagene Autoleucel

Literatures (Medical) associated with Equecabtagene Autoleucel

01 Dec 2024·JAMA Oncology

Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma

Article

Author: Li, Chunrui ; Zhou, Keshu ; Chen, Lijuan ; Mi, Jian-Qing ; Chen, Bing ; Zou, Dehui ; Liu, Jing ; Ren, Hanyun ; Li, Zhenyu ; Song, Yongping ; Ding, Kaiyang ; Huang, He ; Hu, Yongxian ; Hu, Kai ; Liu, Peng ; Li, Jianyong ; Zhang, Xi ; Wang, Wen ; Cai, Songbai ; Qiu, Lugui ; Wang, Di

Importance:

Equecabtagene autoleucel (eque-cel), a fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy, has exhibited potential for the treatment of relapsed or refractory multiple myeloma (RRMM), and further investigation in a larger cohort is necessary.

Objective:

To evaluate whether eque-cel can benefit patients with RRMM and determine the overall response rate postinfusion.

Design, Setting, and Participants:

The FUMANBA-1 trial was a single-arm, open-label, phase 1b/2 trial that evaluated eque-cel in adult patients with RRMM. Enrollment began in April 2020, and patients who received eque-cel will be monitored for a minimum of 15 years following the infusion. As of September 2022, patients with heavily pretreated RRMM who received at least 3 prior courses of therapy from 14 centers were enrolled. Data were analyzed from April 2020 to September 2022.

Interventions:

Patients received a single infusion of eque-cel at 1.0 × 106 CAR-positive T cells/kg after the lymphodepletion.

Main Outcomes and Measures:

Efficacy was the primary objective, and safety, pharmacokinetics, and pharmacodynamics were secondary objectives.

Results:

Of 103 patients who received an eque-cel infusion, 55 (53.4%) were male, and the median (range) age was 58 (39-70) years. A total of 101 patients were evaluable for efficacy. At a median (range) follow-up of 13.8 (0.4-27.2) months, the overall response rate was 96.0% (97 of 101), with 74.3% (75 of 103) achieving a complete response or better. Among the 12 patients who had prior CAR T-cell treatment, 75% (9 of 12) achieved a response. The median progression-free survival was not reached, with a 12-month progression-free survival rate of 78.8% (95% CI, 68.6-86.0). A total of 96 patients (95.0%) achieved minimal residual disease negativity at a sensitivity threshold of 10−5. Adverse events were favorable: 96 of 103 patients (93.2%) experienced cytokine release syndrome (grade 1 to 2 in 95 patients [92.3%]) and 2 (1.9%) experienced immune effector cell–associated neurotoxicity syndrome (grade 1 to 2). All cases of immune effector cell–associated neurotoxicity syndrome and 94 of 96 cases of cytokine release syndrome resolved with treatment. Additionally, only 20 patients (19.4%) developed antidrug antibodies. Cellular kinetic analysis confirmed CAR-positive T cells in all patients, with the longest duration at 735 days.

Conclusions and Relevance:

In this trial, eque-cel led to early, deep, and durable responses in patients with heavily pretreated RRMM with a manageable safety profile. Patients with prior CAR T-cell therapy also benefitted from eque-cel.

Trial Registration:

Chinese Clinical Trial Registry Identifier: ChiCTR2000033946

01 Nov 2024·MOLECULAR THERAPY

Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma

Article

Author: Jiang, Lijun ; Long, Xiaolu ; Ye, Huan ; Yu, Qiuxia ; Wang, Wen ; Du, Aihua ; Hu, Guang ; Li, Zhe ; Wen, Xinyu ; Wang, Di ; Gui, Hongyu ; Zhang, Peiling ; Bao, Yuhan ; Wang, Jue ; An, Ning ; Mu, Wei ; Cai, Songbai ; Li, Chunrui ; Li, Chunhui ; Shu, Chang

CT103A is a fully human chimeric antigen receptor T cell (CAR-T) product for targeting B cell maturation antigen. This study presents the updated safety and efficacy profiles of CT103A in patients with relapsed/refractory multiple myeloma (RRMM) after long-term follow-up. As of July 31, 2023, the median follow-up time after CAR-T cell infusion was 45.0 months (range, 0.7-58.3 months). During long-term follow-up, the incidence of adverse events gradually decreased over time. One patient had a maximum duration of response of nearly 5 years. All 18 patients (100%) achieved partial remission or better; 77.8% (14 of 18) of patients eventually exhibited complete response or stringent complete response (sCR), with response increasing over time. At the time of data cutoff, nine patients were still alive and seven patients had an sCR status with negative minimal residual disease. The median progression-free survival was 22.6 months, and the median overall survival was 50.2 months for all 18 patients. The median CAR transgene persistence was 14.0 months (range, 0.7-57.3 months). Long-term follow-up demonstrated that CT103A confers durable clinical benefit for RRMM patients based on the sustained presence of fully human CAR-T cells.

01 Nov 2023·Molecular diagnosis & therapy

Equecabtagene Autoleucel: First Approval.

Review

Author: Keam, Susan J

Equecabtagene autoleucel (Fucaso^®), an autologous anti-B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy that uses lentivirus as a gene vector to transfect autologous T cells, is being developed by IASO Biotechnology and Innovent Biologics, Inc. for the treatment of multiple myeloma (MM) and autoimmune diseases of the nervous system, including neuromyelitis optica spectrum disorder (NMOSD). Equecabtagene autoleucel was granted conditional approval in China in June 2023 for the treatment of adults with relapsed or refractory MM (RRMM) who have progressed after ≥ 3 lines of therapy (≥ 1 proteasome inhibitor and an immunomodulator). This article summarizes the milestones in the development of equecabtagene autoleucel leading to this first approval in patients with RRMM who have progressed after multiple lines of therapy.

News (Medical) associated with Equecabtagene Autoleucel

28 Mar 2025

·www.prnewswire.com

IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau

SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region (ISAF) has approved the New Drug Application (NDA) for Equecabtagene Autoleucel. This treatment is indicated for adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent. This is the first NDA approval for Equecabtagene Autoleucel outside Mainland China . Equecabtagene Autoleucel (trade name: FUCASO) was approved by China's National Medical Products Administration (NMPA) on June 30, 2023, for treating adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent. On January 29 and February 14, 2025, the NDA for this product for the above indications was formally accepted by the Health Sciences Authority of Singapore and the Department of Health of Hong Kong, China, respectively. The Macau NDA approval is based on data from the pivotal FUMANBA-1 trial (CTR20192510, NCT05066646), a China-based, multi-site, Phase I/II registrational study evaluating the efficacy and safety of equecabtagene autoleucel in patients with relapsed/refractory multiple myeloma (R/R MM). The results demonstrated that equecabtagene autoleucel achieves outstanding efficacy and a favorable safety profile. Ms. Zhang Jinhua, Founder, Chairperson, and CEO of IASO Biotherapeutics, stated: "We are delighted that the New Drug Application (NDA) for equecabtagene autoleucel has been approved by the Macau Drug Administration—the product's first NDA approval outside Mainland China, marking a significant milestone. Through our innovative 'Manufactured in Nanjing, Supplied Globally' model, we will ensure timely access to this CAR-T therapy for multiple myeloma patients in Macau. In December last year, we successfully delivered our Nanjing-manufactured CAR-T therapy to patients in Hong Kong through the Named Patient Program (NPP). Subsequently, in January and February of this year, the NDAs for equecabtagene autoleucel were officially accepted by the Singapore Health Sciences Authority and the Hong Kong Department of Health, respectively. We are actively collaborating with regulatory authorities to advance the approval processes and look forward to delivering clinical benefits to patients in these regions at the earliest opportunity. Meanwhile, IASO Bio remains committed to expanding the global footprint of our CAR-T therapies, dedicated to providing more treatment options for multiple myeloma patients worldwide." About Multiple Myeloma （ MM) Multiple myeloma (MM) is the second most common hematological malignancy globally. According to Globocan data, the global incidence of multiple myeloma in 2022 was 1.8 per 100,000 people, with a 5-year prevalence of 6.8 per 100,000. Despite progress in current anti-myeloma treatments, MM remains largely incurable with multiple relapses and tendency to develop refractoriness to several drug classes, presenting a major therapeutic challenge. Thus, there is an unmet need for new treatment options beyond these current anti-myeloma therapies for the treatment of relapsed or refractory MM, capable of achieving deep and durable responses. About Equecabtagene Autoleucel Equecabtagene Autoleucel is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, FUCASO demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses, providing continuous protection and care for patients with multiple myeloma. About IASO Bio IASO Bio Founded in 2017, IASO Bio is a leading biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of cutting-edge cell therapies and biologics. Initially focused on treatments for blood cancers, the company has strategically expanded into autoimmune diseases. IASO Bio boasts a robust drug development platform, encompassing early discovery to clinical trials, regulatory approval, and commercialization. The company is advancing a diverse pipeline of over 10 innovative products. Notably, Equecabtagene Autoleucel (FUCASO), the world's first fully human CAR-T therapy developed by IASO Bio was approved by Chinese National Medical Products Administration (NMPA) in June 2023 for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent. relapsed/refractory multiple myeloma (R/RMM) in patients at the fourth line and beyond. This product is also in Phase III clinical trials for second and third-line multiple myeloma (MM) and has received Investigational New Drug (IND) approvals in both China and US for autoimmune diseases. Meanwhile, the dual-target (CD19/CD22) product, CT120, for lymphoma is entering Phase II clinical trials. Additionally, RD118, another product targeting GPRC5D for the treatment of R/R MM, has received IND approval in China. In addition to CAR-T therapies, IASO Bio is advancing IASO-782, a fully human anti-CD19 monoclonal antibody. This product has secured IND approvals in China and USA for several autoimmune diseases, with plans to explore additional autoimmune indications. IASO Bio has established multiple global collaborations and licensing agreements with leading cell therapy companies, such as Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, underscoring its superior technology platform and commitment to next-generation cell therapies. With a strong management team, a robust pipeline, high-standard manufacturing and advanced clinical development capabilities, the company is well-positioned to drive innovation. It remains committed to accelerating the development of transformative therapies that address unmet medical needs for patients worldwide. For more information, please visit or . SOURCE IASO Bio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyDrug ApprovalPhase 2Phase 3Cell Therapy

28 Mar 2025

·www.pharmaceutical-technology.com

Macau approves IASO Bio’s multiple myeloma therapy

The Phase I/II trial assessed the therapy’s efficacy and safety in R/RMM subjects. Credit: Volha_R/Shutterstock. The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene autoleucel to treat adults with relapsed or refractory multiple myeloma (R/RMM). This is the first NDA approval for the fully human anti-B-cell maturation antigen (BCMA) CAR-T cell therapy outside Mainland China, offering new hope for R/RMM sufferers who have received three or more previous therapy lines including a minimum of a proteasome blocker and an immunomodulatory agent. Commercially known as Fucaso, the therapy was previously approved by China’s National Medical Products Administration (NMPA) in June 2023. The Health Sciences Authority of Singapore and the Department of Health of Hong Kong, China, accepted the therapy’s NDA for the given indication in January and February 2025 respectively. The latest application is supported by data from the multi-site Phase I/II FUMANBA-1 registrational trial conducted in China, which assessed the therapy’s efficacy and safety in R/RMM subjects. Findings showed that the therapy exhibited a favourable safety profile. IASO Biotherapeutics CEO, founder and chairperson Zhang Jinhua stated: “In December 2024, we successfully delivered our Nanjing-manufactured CAR-T therapy to patients in Hong Kong through the Named Patient Program (NPP). “We are actively collaborating with regulatory authorities to advance the approval processes and look forward to delivering clinical benefits to patients in these regions at the earliest opportunity. Meanwhile, IASO Bio remains committed to expanding the global footprint of our CAR-T therapies, dedicated to providing more treatment options for MM patients worldwide.” IASO Bio entered a research agreement with Umoja Biopharma in November 2022, aiming to develop off-the-shelf therapies for haematological malignancies . Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Drug ApprovalImmunotherapyCell TherapyClinical Study

14 Feb 2025

·www.prnewswire.com

IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health

SHANGHAI and NANJING, China and SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Hong Kong Department of Health (DOH) has officially accepted the New Drug Application (NDA) for Equecabtagene Autoleucel. This treatment is indicated for patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received three or more prior lines of therapies. Equecabtagene Autoleucel (trade name: FUCASO) was approved by China's National Medical Products Administration (NMPA) on June 30, 2023, for treating adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent. As the world's first commercialized fully human CAR-T product, FUCASO has gained recognition from healthcare professionals and patients in China for its remarkable efficacy and safety since its launch. Furthermore, it has also attracted patients from over ten regions/countries to China to receive this innovative therapy. Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Bio, stated: "We are delighted that the New Drug Application for Equecabtagene Autoleucel has been officially accepted by the Hong Kong Department of Health. Hong Kong occupies a 'frontline position' for biopharmaceutical companies in mainland China to expand into global markets, making it a key step in IASO Bio's journey to 'go global.' Thanks to the latest '1+' Mechanism introduced by the Hong Kong Department of Health, we swiftly submitted the NDA. This not only demonstrated our regulatory team's in-depth understanding of and swift response to drug regulatory policies in different regions and countries, but also marks our first successful practice in adopting a flexible and localized registration strategy. We will actively collaborate with the DOH throughout the regulatory process and strive to expedite the launch of this CAR-T therapy in Hong Kong. Fully believing in the outstanding clinical value of Equecabtagene Autoleucel, we have also submitted NDAs in other regions and countries. We remain committed to accelerating access to advanced CAR-T therapies for patients around the world." About Multiple Myeloma （ MM) Multiple myeloma (MM) is the second most common hematological malignancy globally. According to Globocan data, the global incidence of multiple myeloma in 2022 was 1.8 per 100,000 people, with a 5-year prevalence of 6.8 per 100,000. Despite progress in current anti-myeloma treatments, MM remains largely incurable with multiple relapses and tendency to develop refractoriness to several drug classes, presenting a major therapeutic challenge. Thus, there is an unmet need for new treatment options beyond these current anti-myeloma therapies for the treatment of relapsed or refractory MM, capable of achieving deep and durable responses. About Equecabtagene Autoleucel （ FUCASO ） FUCASO (Equecabtagene Autoleucel) is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζ activation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, FUCASO demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses, providing continuous protection and care for patients with multiple myeloma. About IASO Bio IASO Bio Founded in 2017, IASO Bio is a leading biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of cutting-edge cell therapies and biologics. Initially focused on treatments for blood cancers, the company has strategically expanded into autoimmune diseases. IASO Bio boasts a robust drug development platform, encompassing early discovery to clinical trials, regulatory approval, and commercialization. The company is advancing a diverse pipeline of over 10 innovative products. Notably, Equecabtagene Autoleucel (FUCASO), the world's first fully human CAR-T therapy developed by IASO Bio was approved by Chinese National Medical Products Administration (NMPA) in June 2023 for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent. relapsed/refractory multiple myeloma (R/RMM) in patients at the fourth line and beyond. This product is also in Phase III clinical trials for second and third-line multiple myeloma (MM) and has received Investigational New Drug (IND) approvals in both China and US for autoimmune diseases. Meanwhile, the dual-target (CD19/CD22) product, CT120, for lymphoma is entering Phase II clinical trials. Additionally, RD118, another product targeting GPRC5D for the treatment of R/R MM, has received IND approval in China. In addition to CAR-T therapies, IASO Bio is advancing IASO-782, a fully human anti-CD19 monoclonal antibody. This product has secured IND approvals in China and USA for several autoimmune diseases, with plans to explore additional autoimmune indications. IASO Bio has established multiple global collaborations and licensing agreements with leading cell therapy companies, such as Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, underscoring its superior technology platform and commitment to next-generation cell therapies. With a strong management team, a robust pipeline, high-standard manufacturing and advanced clinical development capabilities, the company is well-positioned to drive innovation. It remains committed to accelerating the development of transformative therapies that address unmet medical needs for patients worldwide. For more information, please visit or . SOURCE IASO Bio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2ImmunotherapyDrug ApprovalCell TherapyLicense out/in

100 Deals associated with Equecabtagene Autoleucel

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Refractory Multiple Myeloma	Macao	Nanjing IASO Biotherapeutics Co., Ltd.Startup	28 Mar 2025
Relapse multiple myeloma	Macao	Nanjing IASO Biotherapeutics Co., Ltd.Startup	28 Mar 2025
Multiple Myeloma	China	Innovent Biologics, Inc.	30 Jun 2023
Multiple Myeloma	China	Nanjing Reindeer Biomedical Co., Ltd.	30 Jun 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hashimoto's Encephalitis	Phase 1	China	Nanjing IASO Biotherapeutics Co., Ltd.Startup	22 Sep 2020
Idiopathic Inflammatory Myopathies	Phase 1	China	Nanjing IASO Biotherapeutics Co., Ltd.Startup	22 Sep 2020
Multiple Sclerosis	Phase 1	China	Nanjing IASO Biotherapeutics Co., Ltd.Startup	22 Sep 2020
Myasthenia Gravis	Phase 1	China	Nanjing IASO Biotherapeutics Co., Ltd.Startup	22 Sep 2020
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 1	China	Nanjing IASO Biotherapeutics Co., Ltd.Startup	22 Sep 2020
Neuromyelitis Optica	Phase 1	China	Nanjing IASO Biotherapeutics Co., Ltd.Startup	22 Sep 2020
POEMS Syndrome	Phase 1	China	Nanjing IASO Biotherapeutics Co., Ltd.Startup	22 Sep 2020
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Phase 1	China	Nanjing IASO Biotherapeutics Co., Ltd.Startup	22 Sep 2020
AQP4-IgG positive Neuromyelitis optica spectrum disorder	IND Approval	China	Nanjing Reindeer Biomedical Co., Ltd.	19 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05066646 (FUMANBA-1, ASH2024) Manual	Phase 2	Multiple Myeloma	107	Equecabtagene Autoleucel (high efficacy-to-target ratio group)	qifeunwkch(zczuorluud): HR = 2.3 (95% CI, 1.27 - 4.14), P-Value = 0.0045 View more	Positive	09 Dec 2024
NCT05066646 (FUMANBA-1, ASH2024) Manual	Phase 2	Multiple Myeloma	107	Equecabtagene Autoleucel (a low ratio group)		Positive	09 Dec 2024
NCT05066646 (FUMANBA-1, PRNewswire) Manual	Phase 1/2	Multiple Myeloma	91	伊基奥仑赛 (淋巴细胞清除剂量发生了调整)	hejpinzmme(kaqwgapsps) = sdussbbghy uordneqzem (tfkcazziay ) View more	Positive	29 Sep 2024
NCT05066646 (FUMANBA-1, PRNewswire) Manual	Phase 1/2	Multiple Myeloma	91	伊基奥仑赛 (标准的清淋剂量)	hejpinzmme(kaqwgapsps) = lijyhruttc uordneqzem (tfkcazziay ) View more	Positive	29 Sep 2024
NCT05066646 (FUMANBA-1, IMS2024 \| PRNewswire) Manual	Phase 2	Multiple Myeloma	91	伊基奥仑赛 (肾损组)	hdvitaxcql(almcfgfpui) = 在疗效方面，肾损组的大多数基线特征与非肾损组相当。肾损组也能实现与非肾损组一样快速和深入的缓解。肾损组的长期疗效与非肾损组相当。 xpjhngrezj (xpuoxxgbnd ) View more	Positive	27 Sep 2024
NCT05066646 (FUMANBA-1, IMS2024 \| PRNewswire) Manual	Phase 2	Multiple Myeloma	91	伊基奥仑赛 (非肾损组)		Positive	27 Sep 2024
NCT04561557 (PRNewswire) Manual	Early Phase 1	Autoimmune Diseases of the Nervous System AQP4抗体阳性	12	伊基奥仑赛注射液	kbflmfkmrg(msvedbwvsc) = 良好耐受性和安全性 xacxjvseyb (rxwzehzosc ) View more	Positive	01 Jul 2024
NCT05181501 (FUMANBA-2, EHA 12024 \| EHA 22024) Manual	Phase 1	Multiple Myeloma First line	16	EQUE-CEL	ojzifhniou(usluaagipw) = lddmedcrxz jedmgtdarn (zsjfgucljx ) View more	Positive	14 May 2024
NCT04561557 (Pubmed) Manual	Early Phase 1	Myasthenia Gravis	2	CT103A	kflpmxoilh(hzmkdngwdw) = uedrqygmak pruzdcznrl (xljmyddcvm )	Positive	26 Feb 2024
NCT04561557 (Pubmed \| Proc Natl Acad Sci U S A) Manual	Early Phase 1	Immune-mediated necrotising myopathy	1	Equecabtagene Autoleucel	pncneiotpp(pyormhmuwy) = The patient developed only grade 1 cytokine release syndrome (CRS), but had no immune effector cell-associated neurotoxicity syndrome (ICANS). Only transient hemocytopenia was observed. dshuekqxuh (wrfedihfbu ) View more	Positive	30 Jan 2024
ASH2023	Phase 1	Relapse multiple myeloma	18	CT103A	wkojpwbvks(gclkxzimof) = The recovery of B cells and globulin were observed in 5 and 15 patients, respectively. But for the seven alive patients with sCR, only two of them had B cell recovered. ryrasaqdqo (rtrnwadwik ) View more	Positive	11 Dec 2023
NCT05066646 (FUMANBA-1, ASCO 12023 \| ASCO 22023) Manual	Phase 1/2	Relapse multiple myeloma Last line	103	CT103A	rnoypxemme(hjwjpapxqo) = tjvtuimrla kykrtbeabj (daukvkukku ) View more	Positive	26 May 2023
NCT04561557 (PRNewswire) Manual	Phase 1	Neuromyelitis Optica AQP4 Antibody Positive	12	Equecabtagene Autoleucel	aukyijddqz(tidtlimdsl) = gtrndwoetv pxzuqqxurd (ltdpudgnwg ) View more	Positive	18 Nov 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Equecabtagene Autoleucel

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation